Canada CRE News In Your Inbox.
Sign up for Connect emails to stay informed with CRE stories that are 150 words or less.

Winpak Expects to Invest $80M-$100M in Capital Projects
Packaging manufacturer Winpak expects to post approximately $80 million to $100 million in capital expenditures in 2026.
The planned spending will be highlighted by additional in-mould-label capacity and new converting equipment as the Winnipeg-based company positions itself for growth amid what it describes as a mix of opportunities and challenges heading into the year.
Winpak anticipates healthy organic volume growth and substantial cost savings initiatives in 2026, despite heightened geopolitical and economic uncertainties. The company expects recently added extrusion capacity at its modified-atmosphere packaging facility in Winnipeg to serve as a key growth catalyst, particularly for recycle-ready products.
Over the past year, Winpak secured sizeable new business with major consumer packaged- goods companies and is pursuing further opportunities, especially those that offer sustainability value and help minimize financial exposure related to Extended Producer Responsibility programs. Sales volume growth for 2026 is projected in the range of 2% to 4%.
Market expectations for 2026 suggest overall raw-material prices will remain relatively stable. The majority of U.S. foil import tariffs are expected to continue to be passed through to customers. However, the company cautioned that changes to or elimination of the U.S.-Mexico-Canada free-trade agreement could significantly affect its cost structure.
In response, Winpak will continue optimizing its manufacturing performance, automation, product formulations, raw material procurement and personnel levels. Excluding any potential impact from changes to the trading relationship with the United States, gross profit margins are expected to range between 30% and 31%.
Alongside its capital program, Winpak said it will explore synergistic acquisition opportunities aligned with its core strengths, particularly in medical and pharmaceutical applications. Following positive results from its normal course issuer bid initiative over the past two years, the company is also assessing a renewal of the program, effective March 2026.




